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Abstract 
Recently, we have shown that changes in Fourier transform infrared (FTIR) spectra of living 
MDA-MB-231 cells (a triple negative cell line) upon exposure to anticancer drugs reflect the 
changes in the cellular compositions that is correlated to the modes of action of drugs. In the 
present study, we studied an estrogen receptor expressing breast cancer cell line, MCF7, 
exposed in three anticancer drugs belonging to two well-characterised anticancer classes; 
selective estrogen receptor modulators (SERMs) and DNA-intercalating agent. Firstly, we 
evaluated if the spectral changes in cells are according to the modes of action of drugs and 
the characteristics of the MCF7 cell line in the same way as the MDA-MB-231 cell. Living 
MCF7 cells were treated in the three drugs at IC50 concentration, and the difference spectra 
were analysed using principal component analysis (PCA). The results demonstrated a clear 
separation between tamoxifen/toremifene (SERMs)-treated cells from the doxorubicin (DNA-
intercalator)-treated and untreated cells (control). Tamoxifen and toremifene induced similar 
spectral changes in the cellular compositions of MCF7 cells and lead to the clustering of these 
two drugs in the same quadrant of the principal component 1 (PC1) versus PC2 score plots. 
The separation is mostly attributed to their similar modes of actions. However, doxorubicin-
treated MCF7 cells highlighted spectral changes that are mainly occurred in bands at 1085, 
and 1200-1240 cm-1, which could be associated with the DNA-intercalation effects of the drug. 
Secondly, the pairwise PCA at various individual time points was employed to investigate 
whether the spectral changes of MCF7 and MDA-MB-231 cells in response to the IC50 of 
tamoxifen/toremifene and doxorubicin are dependent on the characteristics of the cell lines. 
The estrogen expressing MCF7 cells demonstrated significant differences in response to the 
SERMs in comparison to the triple negative MDA-MB-231 cells suggesting different modes of 
action have taken place in the two tested cell lines. In contrast, the doxorubicin-treated MDA-
MB-231 and MCF7 cells shows similar changes in the 1150-950 cm-1, which indicates the DNA 
intercalation effect of doxorubicin are found in both cell lines. The results have demonstrated 
that live-cell FTIR analysis is sensitive to the different modes of action from the same drugs 
on cells with different characteristics.  
 Keywords: FT-IR; Live cells, PCA, Vibrational spectroscopy, Anticancer agents, Modes of 
action 
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Introduction 
The development of anticancer drugs is a complex, time-consuming and costly process. It 
takes more than ten years of development and cost approximately $1 billion on average.1, 2 
Despite the excessive efforts intended for inventing new anticancer drugs, the number of new 
drugs has not yet met the increasing demand. The attrition rate is considerably high, and only 
5% of cancer drugs entering clinical trials have successfully reached the marketing approval.3, 
4 As a result, the classical screening approaches (cell-free or cell-based) have been re-
evaluated, and progressively new techniques have been developed. Unlike classical 
approaches, these new techniques provide mechanistic information on the interaction of 
putative drugs with their targets. Metabolomics (the study of metabolites profile in biological 
systems such as cells and tissues) is a promising tool that gives a holistic view on the 
interaction of drugs with cells.5 Various techniques such as mass spectroscopy, nuclear 
magnetic resonance have been employed in metabolomics.6 However, these techniques are 
laborious, destructive and involve high capital cost equipment. Considering these limitations, 
it would be interesting to develop a screening approach based on FTIR spectroscopy. 
 
FTIR spectroscopy is a non-destructive and low-cost technique that can provide a holistic view 
of the chemical composition of biological samples. It is increasingly finding applications in the 
study of drug-cell interaction and present itself as a feasible technique for drug screening.7-9 
Evidence of the effects of drugs on the cells can be inferred by acquiring the IR  spectra of 
drug-treated cells. Several studies established numerous applications including, but are not 
limited to, the assessment of the effectiveness of cancer drugs against several types of cancer 
and distinguishing classes of anticancer drugs based on spectral changes that reflect the 
mode of actions of drugs.10-14 For instance, the effects of four structurally-related anticancer 
cardiotonic steroids on prostate cancer cell line (PC-3) were investigated using FTIR 
spectroscopy, and the results demonstrated that unique spectral signatures can be observed 
from the different cellular pathway between the tested compounds.15 In a similar study, FTIR 
spectroscopy was employed to investigate the response of PC-3 cells to seven anticancer 
drugs belongs to three different classes. It was demonstrated that drugs that are known to 
induce similar effects appeared to cluster closely based on the resemblance of spectral 
features.16 Another study employed synchrotron radiation infrared microspectroscopy to 
distinguish classes of anticancer drugs that are known to have different effects on A2780 
ovarian cancer cells. The results demonstrated a clear distinction between drugs from different 
modes of actions and untreated cells.17  
 
The previously mentioned studies were conducted on chemically fixed or dry cells to benefit 
from the easy handling of the samples and avoid the dominance of water signal in the mid-IR 
regions. These studies provided invaluable biochemical information about changes in the 
cellular compositions in response to treatment; either at a single-cell level or as a population 
of cells. However, the chemical fixation has been shown to cause various changes of 
structures within cells, and hence, it may influence the spectral features of cells exposed to 
anticancer drugs.18-21 The study of live cells in their aqueous environment using FTIR 
spectroscopy has been made available using the multi-reflection attenuated total reflection 
(ATR) sampling method. Although water is a major obstacle in the IR study of live cells,22 the 
spectra of live cells can be acquired with a high signal-to-noise ratio (SNR) using the multi-
reflection ATR approach.23, 24 The proposed in-situ approach provides two main advantages; 
it eliminates the artefacts originated from drying and fixing cells and allows continuous 
monitoring of the response of living cells exposed to anticancer drugs. The latter advantage 
enables a real-time probing of the changes in the major cellular compositions such as proteins, 
nucleic acids and phosphorylated compounds. Therefore, it further enhances the predictability 
of this approach in the study of drug-cell interaction as cellular changes can be tracked at 
different time points in the same experiment.  
 
We have recently shown that ATR FTIR spectroscopy combined with principal component 
analysis (PCA) is a powerful technique to distinguish the response of MDA-MB-231 cells, a 
triple negative cell, based on their different modes of actions. The results have shown that 
drugs with the same mode of action (tamoxifen and toremifene) were clustered together and 
well-separated from the other drugs of different modes of action (imatinib and doxorubicin).25  
 
In the present work, a different cell line, MCF7, which is known to express oestrogen, 
progesterone and HER2 receptor (triple positive) is utilised to evaluate if the different mode of 
actions of the same drug on different cell line can also be distinguished using the live cell FTIR 
approach. MCF7 and MDA-MB-231 cells are both commonly-used breast cancer cell lines as 
an in vitro model to study breast cancer biology. Both cells used in the National Cancer 
Institute (NCI60) screening program and in research for the development of anticancer drugs 
as well as in understanding drug resistance.26 Studies have demonstrated different 
biochemical pathways for the response of MCF7 and MDA-MB-231 cells to the selective 
oestrogen receptor modulators (SERMs) such as tamoxifen and toremifene. The cytotoxicity 
of tamoxifen against the triple negative breast cancer cells (e.g. MDA-MB-231) has shown to 
be mediated through an oestrogen-independent pathway.27 However, tamoxifen induces 
cytotoxicity in MCF7 cells mainly through an oestrogen-dependent pathway.28 To our 
knowledge, this is the first study utilised FTIR spectroscopy to compare two breast cancer 
cells (having different expression level of oestrogen receptor) in response to the same drugs 
and investigate if the induced spectral changes correlate with the different modes of actions. 
Furthermore, the response of MCF7 cells to doxorubicin (DNA-intercalating agent) aimed to 
investigate if the spectral changes of a specific mode of action are similar for both cell lines.  
 
Results and Discussion 
The attachment and growth of MCF7 cells on the ZnS ATR element in the culture medium (i.e. 
L-15 medium) was first examined for the time of the experiment (in total, approximately 72 h 
from seeding the cells). The cells were seeded at high density (~200,000 cells/cm2) to ensure 
a monolayer of cells is formed. Figure 1A shows the typical FTIR spectra of MCF7 cells with 
the absorbance of amide II (1545 cm-1) reproducibly reaching a plateau of ~0.22 a.u. after 72 
h from seeding. The growth of the absorbance of amide II slowed after 24 h of seeding 
suggesting that the cell has reached the plateau phase. This enables the detection of the 
subtle changes in cellular compositions after the addition of the drugs at the 24th hour. The 
averaged spectra of the 24th and 48th hour after seeding the cells from four repeated 
experiments, each from a separate culture, are presented in Figure 1B and C. The high 
reproducibility of the experiment was indicated by the small standard deviation shown.  
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Figure 1: Representative ATR FTIR spectra of MCF7 cells seeded on the ATR element for 72 
h (A). The spectra are an average of four independent FTIR measurements. A straight line 
between 1800-950 cm-1 was used to baseline the spectra. The error bars of the 24th and 48th 
h average spectra presented in (B) and (C), respectively (n=4). The grey colour in (B) and (C) 
indicate the standard deviations of the measurements for every wavenumber (cm-1). 
 
In the previous study, we have demonstrated that studying spectral changes of cells at the 
IC50 (the concentration required to cause 50% reduction in the growth of cells after 24 h) 
produced the most clear grouping of drugs according to their modes of action.25 IC50 is also 
a commonly used concentration in the screening for new drugs and, therefore, it is used as a 
reference concentration in this study to normalise the possible variations in the performance 
of the drugs due to differences in the rate of drug uptake and transport. The percentage 
viability of MCF7 treated with tamoxifen, toremifene and doxorubicin for 24 hours were 
determined by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay are 
shown in (Figure 2, A-C) and in Table 1. 
-0.05
0
0.05
0.1
0.15
0.2
900100011001200130014001500160017001800
A
b
s
o
rb
a
n
c
e
Wavenumber (cm-1)
24 hB
-0.05
0
0.05
0.1
0.15
0.2
0.25
900100011001200130014001500160017001800
A
b
s
o
rb
a
n
c
e
Wavenumber (cm-1)
48 hC
   
 
Figure 2: Viability percentage of MCF7 cells seeded in L-15 medium and treated with 
tamoxifen (A), toremifene (B), and doxorubicin (C) for 24 h. Data are presented as mean ± 
SD of three independent MTT assays. 
 
Table 1: Summary of the calculated IC50 against MCF7 cells and the mode of actions of drugs 
used in this study.  
Drug Mode of Action IC50 (µM) 
 
Tamoxifen 
Selective Oestrogen Receptor Modulator (SERMs) also 
known as Oestrogen-Dependent Pathway mainly in ER-
positive breast cancer (e.g. MCF7) 
 
~14.5 
 
Toremifene 
Selective Oestrogen Receptor Modulator (SERMs) also 
known as Oestrogen-Dependent Pathway mainly in ER-
positive breast cancer (e.g. MCF7) 
 
~23.3 
Doxorubicin DNA-Intercalating Agent ~ 2.1 
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The effect of tamoxifen and toremifene on the oestrogen positive breast cancer (e.g. MCF7) 
are believed to be mediated through competitive binding to oestrogen receptors (ER) against 
oestrogen, which is also known as a classical genomic mechanism. Other studies also 
suggested a non-genomic mechanism that is mediated through the epidermal growth factor 
receptor (EGFR), which leads to sustained phosphorylation of ERK 1/2 in ER-positive cancer 
cell lines (MCF-7 and T47D).28, 29 Doxorubicin is a broad spectrum anthracycline anticancer 
agent that is very effective in the treatment of many cancer types and widely used in the 
treatment of breast cancer cells.30 The in vitro effect of doxorubicin on the MCF7 and MDA-
MB-231 cells is well-established. For example, some studies have shown multiple 
mechanisms at the molecular level of the doxorubicin DNA intercalation effects in breast 
cancer, which eventually leads to the induction of apoptosis and cells death.31  
 
The acquired data were pre-processed as previously described.25 The first spectrum 
measured immediately after adding the drugs was used as a background, which was ratioed 
to subsequent spectra to obtain the difference spectra. The difference spectra underline the 
subtle spectraI changes of cells after the introduction of anticancer drugs. Since spectra were 
collected at 20 min intervals, many time-points can be analysed individually. To maintain the 
simplicity of the presentation, vector normalised difference spectra acquired at the 2nd, 4th and 
6th hours of exposure to drugs have been selectively presented in (Figure 3, A-C). The 
difference spectra of untreated cells (control) mainly highlights the typical spectrum of cells 
due to the continual incremental growth of the cell, as previously shown in (Figure 1). In 
comparison to the control, the drug-treated MCF7 cells demonstrated different spectral 
changes mainly in the 1240-950 cm-1 region where absorbance peaks of cellular components 
such as nucleic acids, phosphorylated compounds and carbohydrates can be identified. 
Tamoxifen and toremifene, which belongs to the same class of anticancer drugs (i.e. SERMs) 
prominently show similar spectral changes that are different from the control and the 
doxorubicin-treated cells. Furthermore, the doxorubicin-treated MCF7 cell spectrum shows a 
reduction in the absorbance of peaks at 1085 cm-1 and 1050 cm-1 regions at the 2nd hours of 
exposure, which become more apparent at the 4th and 6th hours of exposure, while amide II 
bands ~ 1545 cm-1 showed no significant changes (Figure 3, B and C). These changes have 
been previously recognised in PC-3 cells treated with 1.0 µM doxorubicin and in MDA-MB-
231 cells treated with IC50 of doxorubicin (~3 µM), which is attributed to the breakage of the 
phosphates backbone of the DNA because of the intercalation effect of doxorubicin.24, 25   
 
  
 
Figure 3: FTIR (vector normalised) difference spectra of live MCF7 cells after exposure to 
0.1% DMSO (drug vehicle; control(C)) and IC50 of tamoxifen (TM), toremifene (TR), and 
doxorubicin (DX) for 2, 4 and 6 h (A, B, and C, respectively). The spectra presented are an 
average of four repeated measurements for each condition. Refer to (supplementary Figure 
S5) for the average spectra with error bars. 
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Principal component analysis (PCA) of the difference spectra of control and drug-treated 
MCF7 cells are shown in Figure 4. The score (which highlights the “intensity”) and the 
corresponding loading (which highlights the spectral pattern) plots of first two PCs at 2nd, 4th 
and 6th hours of live MCF7 cells exposed to the IC50 of tamoxifen, toremifene and doxorubicin 
are shown in Figure 4 A-C, respectively. First, it can be observed that the score plots of PC1 
versus PC2 of the 2nd, 4th and 6th hour clearly separated tamoxifen/toremifene treated MCF7 
cells from doxorubicin-treated and from untreated cells (control). Most importantly, tamoxifen 
and toremifene-treated MCF7 cells always clustered relatedly, which again confirmed the 
remarkable similarity observed from the difference spectra shown in Figure 3, A-C. 
Additionally, the PCA loading plots demonstrated a time-dependent spectral change in which 
the loadings of PC1 and PC2 in the 2nd hour of exposure is different from that of 6th hour of 
exposure. In Figure 4A, for example, the PC1 of the 2nd hour (accounted for 57.58% of the 
major variances) mainly separated tamoxifen/toremifene-treated MCF7 cells from 
doxorubicin-treated cells and control and highlighted spectral changes at 1020, 1087, 1172, 
1225, 1410 and 1508 cm-1. The peaks at 1172, and 1508 cm-1 overlaps with the spectrum of 
tamoxifen and toremifene and are possibly indicative of drug accumulations in the cells (refer 
to Supplementary Figure S6). However, other peaks that are notably detected in the same 
PC1 loadings are not originated from the absorbance of the drugs and accounted for the 
grouping as well. PC2 score (22.20% of the variances) and loading plots of the 2nd hour 
exposure highlighted changes at 1200-1240 and 1085 cm-1 and mainly separated doxorubicin-
treated cells from control as presented in (Figure 4A). These bands are characteristic of the 
asymmetric (~1237 cm-1) and symmetric phosphodiester vibrations of nucleic acids (~1085 
cm-1) and could be an indication of DNA-intercalating mechanism of doxorubicin. The score 
plot of PC1 versus PC2 for the 4th hour shown in (Figure 4B) once again provided a grouping 
of the drugs in a similar pattern (with an inverted sign) as previously observed in the 2nd hour 
exposure (Figure 4A). The PC1 represented 58.40% of the variances and separated 
tamoxifen/toremifene-treated MCF7 cells from doxorubicin-treated cells and control and 
highlighted the same spectral changes as observed in Figure 4A (with an inverted sign). 
Compared to the 2nd hour of exposure, the contribution of tamoxifen/toremifene accumulations 
peaks (i.e. bands at 1508 and 1172 cm-1) was weaker. At the 6th hour of exposure, the score 
plot of PC1 versus PC2 continues to show a clear separation between the drugs with different 
mode of actions as shown in Figure 4C. However, PC1 (49.53% of the variances) mainly in 
this case separated doxorubicin-treated cells from tamoxifen/toremifene and untreated cells. 
The PC1 loadings remarkably highlighted spectral changes at 1240-1200 and 1085 cm-1 that 
are associated with DNA-intercalating effects of doxorubicin as previously discussed. PC2 
mainly separated tamoxifen/toremifene-treated MCF7 cells and highlighted spectral changes 
similar to the PC1 at the 2nd and 4th hour of treatment with a diminished contribution from the 
1508 cm-1 band.  
 
 
Figure 4: PCA scores and their corresponding loadings of FTIR vector normalised difference 
spectra of live MCF7 cells after exposure to 0.1% DMSO (Control) and IC50 of tamoxifen 
(TM), toremifene (TR), and doxorubicin (DX) in the 2nd h (A), 4th h (B) and 6th h (C). Vertical 
lines were added to the loading plots to aid in the comparison between the different hours of 
treatment.  
 
Importantly, the PCA loadings of the live MCF7 cells exposed to drugs at different time points 
grouped drugs according to their modes of actions and remarkably highlighted spectral 
changes in the 1250-950 cm-1 region. Absorbance peaks in this particular region are indicative 
of changes in the asymmetric PO2- of nucleic acids,  phosphorylated proteins (~1237 cm-1), C-
O of carbohydrates and proteins side chains (~1150 cm-1), symmetric PO2- of nucleic acids 
and PO42- phosphorylated proteins, C-O-C and C-O-P of polysaccharides (~1080 cm-1), C-O 
of carbohydrates (~1050-1036 cm-1) and PO42- of phosphorylated proteins and nucleic acids 
(~990-970 cm-1). It is worth mentioning that spectral changes in the 1250-950 cm-1 region have 
been previously demonstrated in MDA-MB-231 cells exposed to the IC50 of 
tamoxifen/toremifene, imatinib and doxorubicin. In a similar approach to the one employed in 
this study, PCA of the 2nd, 4th and 6th hours grouped drugs with a similar mode of actions in 
the same cluster while drugs with different modes of actions were clustered separately.25 
Further investigation, as we shall discuss later, will underline if the spectral changes due to 
the exposure to the same drug will be similar in different cell lines with different properties.  
 
Comparison Between MCF7 and MDA-MB-231 Cells 
The response of MCF7 and MDA-MB-231 cells treated with the IC50 of tamoxifen, toremifene 
and doxorubicin have been investigated to determine whether the different modes of action of 
the same drug in different cell lines can be detected using the live cell FTIR approach. The 
results from the pairwise PCA (SERM drugs-treated versus control) for the MCF7 and MDA-
MB-231 cells at a specific length of time of exposure are shown in Figure 5 and 7. In all 
pairwise PCA, PC1 represented more than 70% of the variances and is the only PC that 
provides a clear separation between the drug-treated cells and the control cells. . The pairwise 
PCA of the spectral response of MCF7 cells and MDA-MB-231 has shown a clear separation 
after the 2nd hour of exposure to the IC50 tamoxifen/toremifene (Figure 5, A-C). Although 
similar spectral changes were detected in the 1600-1400 cm-1 region, remarkably difference 
can be observed in the 1400-900 cm-1 region suggesting these drugs has different modes of 
actions in the MCF7 and MDA-MB-231 cells. Tamoxifen/toremifene are known SERMs, and 
their classical modes of actions in ER-positive cancer cells (i.e. MCF7) are mainly mediated 
through their competition with oestrogen for binding to the oestrogen receptor (ER), which 
eventually lead to the induction of cell death. The MDA-MB-231 cells, also known as triple 
negative cells, lack the expression of ER, progesterone receptor (PR) and human epidermal 
growth factor receptor 2 (HER2). The cytotoxicity of tamoxifen against MDA-MB-231 is well-
established and demonstrated to be mediated through the inhibition of protein phosphatase 
2A (CIP2A) and phospho-Akt (p-Akt).27, 32 Moreover, tamoxifen induces cells death in both ER-
positive (MCF7) and ER-negative (MDA-MB-231) cells by rapid mitochondrial death program 
that involves an increase in the production of reactive oxygen species (ROS), the release of 
cytochrome c and decrease in the mitochondrial membrane potential.28, 33 The dissimilarity in 
the response of MCF7 and MDA-MB-231 cells to tamoxifen/toremifene at the same cytotoxicity 
level (i.e. IC50) reflected the different modes of actions of tested drugs on these two cell lines.  
  
Likewise, the pairwise PCA of the response of MCF7 cells and MDA-MB-231 after the 2nd hour 
of exposure to the IC50 of doxorubicin are shown in (Figure 6, A-C). The PC1 loadings of 
MDA-MB-231 cells (black spectrum) and MCF7 cells (red spectrum), to some extent, show 
similarity in the 1150-950 cm-1 region with a significant decrease in absorbance of the band at 
1087 cm-1. This band is mainly associated with the symmetric phosphodiester vibrations of 
nucleic acids (~1085 cm-1), which is expected from the DNA-intercalating effects of 
doxorubicin in these two cell lines. The differences in response observed in the 1250-1150 
cm-1 possibly originated from other cellular metabolites that are originated from upstream or 
downstream signalling cascades due to the DNA-intercalations. As previously mentioned, 
different mechanisms have been demonstrated to explain the role of doxorubicin in the DNA-
intercalation such as the generation of free radicals, inhibition of topoisomerase II enzyme and 
the interference of helicase activity and DNA unwinding.31, 34 Doxorubicin has also been 
demonstrated to induce transcriptional changes with many variations between cell types.35, 36 
The pairwise analysis of the 4th and 6th hr of MCF7 and MDA-MB-231 cells in response to each 
of the drugs demonstrated similar spectral changes (PCs loadings) to the 2nd hour and the 
results are presented in (see supplementary, Figures S7 and S8). 
 
 Figure 5: (A) shows the pairwise PC1 scores of MDA-MB-231 cells for control (1-3) versus 
tamoxifen (4-6) and toremifene (7-9). (B) represents the pairwise PC1 score of MCF7 cells for 
control (1-4) versus tamoxifen (5-7) and toremifene (8-10). (C) demonstrates the 
corresponding PC1 loadings of MDA-MB-231 cells (black spectrum) and MCF7 (red spectrum) 
after the 2nd h of exposure to the IC50 of tamoxifen/toremifene. 
 
 
 
 Figure 6: (A) shows the pairwise PC1 scores of MDA-MB-231 cells for control (1-3) versus 
doxorubicin (4-6). (B) represents the pairwise PC1 scores of MCF7 cells for control (1-4) 
versus doxorubicin (5-8). (C) demonstrates the corresponding PC1 loadings of MDA-MB-231 
cells (black spectrum) and MCF7 (red spectrum) after the 2nd hour of exposure to the IC50 of 
doxorubicin. 
 
Conclusion 
In this study, live-cell FTIR spectroscopy has been demonstrated as a powerful technique to 
distinguish the modes of actions between different drugs on the same cell line and the different 
response to the same drug fromcell lines of different characteristics. The difference spectra of 
MCF7 cells treated in IC50 of tamoxifen and toremifene, which belong to the same anticancer 
class (SERMs), show remarkable similar spectral changes. However, doxorubicin treated 
MCF7 cells presented spectral changes that are different from cells treated in 
tamoxifen/toremifene. These changes mainly occurred in the spectral regions at 1085, and 
1200-1240 cm-1, which could be associated with the DNA-intercalation effects of doxorubicin. 
The pairwise PCA confirms that MCF7 cells responded differently to the SERMs in comparison 
to the triple negative MDA-MB-231 cells when treated in the SERMs, which is another 
evidence of the cell line-dependent modes of actions of these drugs. These results are in good 
agreement with several studies, which have shown that SERMs can induce their cytotoxic 
effect either in an oestrogen-dependent pathway (for oestrogen-positive cells such as MCF7) 
or oestrogen-independent pathway (for oestrogen-negative cells such as MDA-MB-231). 
 
Furthermore, the pairwise PCA of doxorubicin-treated cells demonstrated a remarkable 
similarity between the two cell lines in the 1150-950 cm-1 regions, highlighting the DNA 
intercalating effect of the drug, but some variations were observed at 1200-1250 cm-1. This 
indicates that the response of different breast cancer cells to doxorubicin is not entirely the 
same, and several types of breast cancer cells should be tested in the future. In summary, 
live-cell FTIR method holds a promising potential in distinguishing drugs according to their 
modes of action. A further collection of live-cell data will help in designing a discrimination 
model to predict the modes of action of anticancer molecules and eventually can be employed 
in pre-clinical screening for novel anticancer drugs.  
 
 
Experimental Section 
Multi-bounce ATR-FTIR accessory 
A 10-reflection (10 internal reflections on the sample side) ATR accessory trough plate (HATR, 
Pike technologies) controlled at 37 C̊ with a 45° ZnS ATR element (80 mm X 10 mm X 4 mm, 
Crystan Ltd., UK) was used. A schematic is shown in Figure 7. The effective path length 
obtained in the living cells produced from this accessory is approximately 20-30 µm, with a 
depth of penetration (dp) nearly 2-3 µm. The trough plate has a measurement surface of about 
500 mm2, where live cells adhere and continuously measured. 
 
Figure 7: A schematic describing the ATR element and the cell culture set up for the live cells 
FTIR measurement. An IR beam from the interferometer is shone on the live cells intimately 
adhered to ATR surface and undergoes internal reflections. The generated evanescent wave 
penetrates (~2-3 µm) and absorbed by the sample (cells), which then converted to an ATR 
absorbance spectrum by Fourier transform.   
 
Live cell preparation 
MCF7 cells were maintained in T25 cell culture flasks using DMEM high glucose medium with 
10% FBS, 1% MEM NEAA, 2 mM L-glutamine, 100 U/mL penicillin and 100 U/mL streptomycin 
and incubated in a 5% CO2 and 37°C incubator. The cells were trypsinised and harvested 
when they reached ~80% confluence and then centrifuged into a pellet. The pellet was then 
re-suspended in L-15 medium, supplemented with 10% FBS, 1% MEM NEAA, 2 mM L-
glutamine, 100 U/mL penicillin and 100 µg/mL streptomycin, to reach a cell density of ~ 5.0 x 
105 cells/mL and total of 2.0 mL of suspension (i.e. ~ 1.0 X 106 cells). The cell suspension was 
directly seeded onto the multi-reflection trough plate controlled at 37 °C and sealed with a 
heated glass cover lid at 37 °C, to control the temperature in the measurement chamber. After 
24 hours of incubation, the high seeding density ensured that cells are attached to the 
measurement surface as a monolayer with high (~90%) confluence. A reflective optical 
microscope with a 10x objective (L2003 microscope fitted with a digital camera) was used to 
confirm the confluence and attachment of cells to the measurement surface (see 
supplementary Figure S1).  
Determination of cell viability 
The viability of cells was determined using the standard MTT (3-(4,5- dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide) assay.37 In brief, suspension of MCF7 cells (2 x 104 cells per 
well) in L-15 medium was seeded in a 96-well plate and allowed to grow for 24 hours at 37 °C 
to reach a comparable confluence (~90%) to the ATR-FTIR experiment. The medium was 
then replaced with the L-15 medium, which contains different concentrations of tamoxifen, 
toremifene (dissolve in DMSO) and doxorubicin (dissolved in water) and incubated at 37 °C 
for 24 hours. In all treatments, the final concentration of DMSO was maintained at 0.1%. 
Afterwards, the supernatant of each well was removed, washed once with PBS medium and 
replaced with 100 µL (0.5 mg/mL) of MTT in L-15 medium. The 96-well plate was incubated 
for 3 hours before discarding the MTT solution. In the last step, 100 µL per well of DMSO was 
added to dissolve the resulted formazan product and the absorbance was measured at 570 
nm, with the reference at 630 nm, in a Spectra MAX 190 multi-well plate reader. The relative 
cell viability percentage was calculated by comparing the absorbance of treated cells with 
control, where 0.1% DMSO in L-15 medium was applied instead of the drug solution. 
GraphPad Prism® was used to calculate the IC50 and data presented as mean ± SD.  
 
FTIR measurement of samples 
An FTIR spectrometer (Frontier, Perkin Elmer Ltd., UK) fitted with a room temperature 
deuterated triglycine sulfate (DTGS) detector. After seeding the cells in the ATR trough plate 
for 24 hours, the cells attached to the ZnS ATR element were exposed to the IC50 of 
tamoxifen, toremifene and doxorubicin by adding appropriate amounts of 50 mM stock solution 
in the L-15 medium and maintain a total of 0.1% DMSO. Cell spectra were measured by 
averaging ~237 scans (scanning time of 11 minutes) and were acquired every 20 minutes so 
that three spectra were collected hourly (i.e. 144 spectra were collected within the 48 hour 
period). The IR spectrum of cells measured in spectral region of 2000 to 900 cm-1 with a 
spectral resolution of 8 cm-1 and 0.2 cm/s mirror speed. A strong Norton-Beer apodization 
function and self-phase correction selected for the interferogram process. Spectrum 10 
software (Perkin Elmer Ltd., UK) used for the data processing, including baseline and the 
water vapour correction. Spectra of cells were continuously monitored from the moment after 
seeding the cells on the ATR element for 24 hours. For control, DMSO was added to the 
medium on the ATR trough to reach a concentration of 0.1% and measured for another 24 
hours. A spectrum of L-15 medium was used as a background to obtain the full spectra of cells 
with the water vapour subtracted. For difference spectra, the first spectrum of cells 
immediately after the addition of drugs was used as a background to highlight the changes in 
live cells (see supplementary Figure S2). All experiments were repeated at least three times.   
Principal Component Analysis (PCA) 
PCA was carried out using PyChem Software (http://pychem.sourceforge.net/).38 This analysis 
was applied to reduce the dimension of the spectroscopic data. Correlation matrix and 
Nonlinear Iterative Partial Least Squares (NIPALS) were selected for the PCA analysis. The 
data pre-processing performed as previously described in 25. Briefly, the spectral wavenumber 
range was truncated to 1800-900 cm-1, and then an interactive baseline correction using the 
Spectrum 10 software (Perkin Elmer) was performed based on the minima absorbance at 
2000, 1800, 1757, 1480, 1000 and 950 cm-1. Vector normalisation was calculated in Microsoft 
®Excel 10, in which spectra were divided by the square root of the sum of the mean intensities 
squared. PCA was applied to analyse spectra extracted from different time points after the 
addition of drugs. The analysis was focused on the first two principle components (i.e. PC1 
and PC2) as they accounted for more than 85% of the variances (Supplementary, Figure 
S3).  The amide I region (~1640 cm-1) was excluded in the PCA as the water peak at this 
region exceeded 1, which indicates that the detector will not operate in a linear response at 
this band (Supplementary, Figure S4).23, 39 
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